EUVIMEDEUVIMED entdecken
Crossref

Kinetics of cellular and humoral immunogenicity and effectiveness of SARS‐CoV ‐2 booster vaccination in hematologic neoplasms

Moraima Jiménez iD, Candela Fernández-Naval, Víctor Navarro iD, Sandra Novoa, Mónica Martinez-Gallo, Daniel Medina, Cristina Andrés, Andrés Antón, Soraya Peralta, Gemma Pujadas, Cristina Hernández, Carlota Pagès und 11 weitere

American Journal of Hematology · 2023-08 · 98 (8) · 1204-1213

DOI: 10.1002/ajh.26951 ↗

Kurz gefasst

Fachartikel in der Zeitschrift American Journal of Hematology, online erschienen am 08.05.2023. Verfasst von Moraima Jiménez und 22 weiteren Autor:innen. Beteiligte Einrichtung: Servei d'Hematologia, Vall d'Hebron Hospital Universitari, Experimental Hematology, Vall d'Hebron Institute of Oncology (VHIO), Vall d'Hebron Barcelo…. Hauptthemen laut MEDLINE: COVID-19, Hematologic Neoplasms, Lymphopenia. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 48 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Data on the effect of booster SARS‐CoV‐2 vaccination are mainly focused on humoral immunogenicity, while the kinetics of vaccine‐induced cellular response and its correlation with effectiveness in hematologic patients are less explored. Our aim was to evaluate the longitudinal cellular and humoral immunogenicity induced by two and three doses of the mRNA‐1273 SARS‐CoV‐2 vaccine in 270 patients with hematologic malignancies, and its relationship with the severity of breakthrough SARS‐CoV‐2 infection. Results indicate that at 23 weeks after the second dose, the seroconversion rate declined from 68.5% to 59.3%, with a reduction in median anti‐S titers from 1577 to 456 BAU/mL, mainly in patients over 65 years of age or chronic lymphocytic leukemia (CLL) patients undergoing active therapy. Cellular immunogenicity, however, remained positive in 84.4% of cases. A third vaccine dose seroconverted 42.7% (41/96) and triggered cellular response in 36.7% (11/30) of previously negative patients. Notably, only 7.2% (15/209) of patients failed to develop both humoral and cellular response. Active therapy, anti‐CD20 antibodies, lymphopenia, hypogammaglobulinemia, and low CD19 + cell count were associated with poor humoral response, while active disease, GvHD immunosuppressive therapy, lymphopenia, and low CD3 + , CD4 + , CD56 + cell count determined an impaired cellular response. After 13.8 months of follow‐up, the incidence of SARS‐CoV‐2 infection was 24.8% (67/270), including 6 (9%) severe/critical cases associated with a weaker cellular (median interferon gamma (IFN‐γ) 0.19 vs. 0.35 IU/mL) and humoral response (median anti‐S titer

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

COVID-19Hematologic NeoplasmsLymphopeniaHumansCOVID-19 VaccinesSARS-CoV-2VaccinationAntibodiesAntibodies, Viral

Substanzen

COVID-19 VaccinesAntibodiesAntibodies, Viral

Autor:innen und Institutionen

  • Servei d'Hematologia, Vall d'Hebron Hospital Universitari, Experimental Hematology, Vall d'Hebron Institute of Oncology (VHIO), Vall d'Hebron Barcelona Hospital Campus, Barcelona, Spain.
  • Department of Medicine, Universitat Autònoma de Barcelona, Bellaterra, Barcelona, Spain.
  • Department of Microbiology, Vall d'Hebron Hospital Universitari, Vall d'Hebron Institut de Recerca (VHIR), Vall d'Hebron Barcelona Hospital Campus, Barcelona, Spain.
  • Oncology Data Science (ODysSey) Group, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain.
  • Department of Immunology, Vall d'Hebron Hospital Universitari, Vall d'Hebron Research Institute, Vall d'Hebron Barcelona Hospital Campus. Department of Cell Biology, Physiology and Immunology, Autonomous University of B…
  • Experimental Hematology, Vall d'Hebron Institute of Oncology (VHIO), Vall d'Hebron Barcelona Hospital Campus, Barcelona, Spain.

ORCID-Profile: Moraima Jiménez, Víctor Navarro, Mercedes Gironella

Zitieren

APA

Jiménez, M., Fernández-Naval, C., Navarro, V., Novoa, S., Martinez-Gallo, M., Medina, D., Andrés, C., Antón, A., Peralta, S., Pujadas, G., Hernández, C., Pagès, C., Roldán, E., Pumarola, T., Gironella, M., Ruiz-Camps, I., Martínez-Gómez, X., Valcárcel, D., Hernández, M., …, & Abrisqueta, P. (2023). Kinetics of cellular and humoral immunogenicity and effectiveness of SARS‐CoV ‐2 booster vaccination in hematologic neoplasms. American Journal of Hematology, 98(8), 1204-1213. https://doi.org/10.1002/ajh.26951

Vancouver

Jiménez M, Fernández-Naval C, Navarro V, Novoa S, Martinez-Gallo M, Medina D, et al. Kinetics of cellular and humoral immunogenicity and effectiveness of SARS‐CoV ‐2 booster vaccination in hematologic neoplasms. American Journal of Hematology. 2023;98(8):1204-1213. doi:10.1002/ajh.26951

BibTeX
@article{Jimnez2023,
  author = {Jiménez, Moraima and Fernández-Naval, Candela and Navarro, Víctor and Novoa, Sandra and Martinez-Gallo, Mónica and Medina, Daniel and Andrés, Cristina and Antón, Andrés and Peralta, Soraya and Pujadas, Gemma and Hernández, Cristina and Pagès, Carlota and Roldán, Elisa and Pumarola, Tomás and Gironella, Mercedes and Ruiz-Camps, Isabel and Martínez-Gómez, Xavier and Valcárcel, David and Hernández, Manuel and Bosch, Francesc and Crespo, Marta and Esperalba, Juliana and Abrisqueta, Pau},
  title = {Kinetics of cellular and humoral immunogenicity and effectiveness of SARS‐CoV ‐2 booster vaccination in hematologic neoplasms},
  journal = {American Journal of Hematology},
  year = {2023},
  volume = {98},
  number = {8},
  pages = {1204--1213},
  doi = {10.1002/ajh.26951}
}
Kostenlos starten →